Open AccessHistological transformation from non‐small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor‐tyrosine kinase inhibitor
Author(s) -
Kim WooJin,
Kim Sunmin,
Choi Hayoung,
Chang Jinsun,
Shin HongJoon,
Park CheolKyu,
Oh InJae,
Kim KyuSik,
Kim YoungChul,
Choi YooDuk
Publication year - 2015
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12217
Subject(s) - medicine , epidermal growth factor receptor , etoposide , lung cancer , tyrosine kinase , cisplatin , tyrosine kinase inhibitor , cancer research , epidermal growth factor , carcinoma , oncology , chemotherapy , small cell lung carcinoma , pathology , small cell carcinoma , receptor , cancer
Several cases of acquired resistance in patients with activating epidermal growth factor receptor ( EGFR ) mutation have been reported. However, rare clinical cases exist of a transformation to small cell lung cancer ( SCLC ) following treatment with EGFR ‐tyrosine kinase inhibitors ( TKIs ). We report a case of non‐small cell lung cancer ( NSCLC ) with L858R mutation at the time of diagnosis. After failure of EGFR‐TKI therapy, we performed additional histopathologic examinations. We confirmed that the patient had a histological transformation from NSCLC to SCLC . We performed chemotherapy with etoposide and cisplatin against the SCLC and radiologic findings were improved.